The ABCardionostics project is pleased to announce that several of its key innovations have been selected and published on the European Commission’s Innovation Radar platform. This recognition highlights the strong innovation capacity of the project and its potential to generate impactful solutions in the field of cardiovascular diagnostics and therapeutics.
Following an independent assessment by the Innovation Radar, three ABCardionostics innovations have been identified as Business Ready, with high to very high market creation potential.
Selected innovations of ABCardionostics
- Novel antibody biotracers – Radiolabeled small human antibody fragments for imaging the vessel wall with PET. These antibodies may reveal early or progressing plaques and help to diagnose and predict disease outcome.
- Therapeutic profiles of HuAbs and bsAbs – Bigger human antibody formats will be tested for their therapeutic efficacy. Successful completion of these tests will yield innovative human antibody-based biologics for atherosclerosis treatment.
- Validated plaque biomarkers – The new human antibody radiotracers may help to identify new molecular targets with diagnostic, prognostic and/or therapeutic value.
More details are available on the Innovation Radar platform: https://innovation-radar.ec.europa.eu/
What is the Innovation Radar?
The Innovation Radar is an initiative of the European Commission aimed at identifying high-potential innovations and key innovators emerging from EU-funded research projects. It evaluates innovations based on their maturity, market readiness and potential to create new markets or disrupt existing ones.
By featuring on the Innovation Radar, innovations gain greater visibility among investors, industry stakeholders, policy makers and innovation ecosystems, supporting their further development and uptake.
What does this mean for ABCardionostics?
The inclusion of ABCardionostics results on the Innovation Radar highlights the strong innovation potential of the project. The identified innovations represent promising outcomes that have been recognised based on their expected maturity and market potential.
While these innovations are classified as Business Ready by the Innovation Radar methodology, their full development, validation and exploitation are planned to be achieved during the coming years of the project. Our consortium will continue working towards delivering these results, ensuring their scientific robustness and paving the way for their future translation into real-world cardiovascular diagnostic and therapeutic solutions.